SPOTLIGHT: King asks FDA to block ZymoGenetics' drug
King Pharmaceuticals has petitioned the FDA not to approved ZymoGenetics' rThrombin, a treatment for surgical bleeding. King claims that ZymoGenetics' drug has not been sufficiently tested and that it poses a risk to the public if approved. Why is King so interested? Well, because the company makes a competing version of the drug and stands to lose market share if a new version of the product is approved. If the FDA takes the request into account, it could be a major setback for ZymoGenetics. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
